Evidence map›Paper›PMID 40055603›Full record

ReviewBMC medical research methodology2025

The use of race and ethnicity in sickle cell disease research.

Aida S Kidane Gebremeskel, Minke A Rab, Erik D van Werkhoven, Teun B Petersen, Marjon H Cnossen, Amade M'charek, Karlijn A C Meeks, Anita W Rijneveld

Abstract readReview
In one paragraph

Review in BMC medical research methodology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aida S Kidane GebremeskelDepartment of Pediatrics, Pediatric Hematology, Erasmus Medical Center, Dr. Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands. aida.kidane.sci@gmail.com.ORCID 0000-0003-0591-3004
Minke A RabDepartment of Hematology, Erasmus Medical Center Cancer Institute, Dr. Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands.
Erik D van WerkhovenDepartment of Hematology, Erasmus Medical Center Cancer Institute, Dr. Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands.
Teun B PetersenDepartment of Biostatistics, Erasmus Medical Center, Dr. Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands.
Marjon H CnossenDepartment of Pediatrics, Pediatric Hematology, Erasmus Medical Center, Dr. Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands.
Amade M'charekAnthropology, University of Amsterdam, Nieuwe Achtergracht 166, Amsterdam, North Holland, 1018WV, The Netherlands.
Karlijn A C MeeksCenter for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, 12 South Drive Bldg 12A ste 1025, Bethesda, MD, 20892-5611, USA.
Anita W RijneveldDepartment of Hematology, Erasmus Medical Center Cancer Institute, Dr. Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands.

Funding

Research within the Section on Social and Cognitive Developmental Neuroscience ZIAMH002986 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI WHITE, TONYA · 2023 to 2025
$6.3M
Unravelling the Role of Epigenetics and Cytokines in Type 2 Diabetes among African-ancestry PopulationsR00DK131018 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI Karlijn Anna Catharina Meeks · 2025 to 2026
$492k
Unravelling the Role of Epigenetics and Cytokines in Type 2 Diabetes among African-ancestry PopulationsK99DK131018 · NIDDK · NATIONAL HUMAN GENOME RESEARCH INST · PI MEEKS, KARLIJN ANNA CATHARINA · 2023 to 2023
$0k
Intramural NIH HHS ZIA MH002986NIDDK NIH HHS K99 DK131018NIDDK NIH HHS R00 DK131018NIH Pathway to Independence Award K99/R00 DK131018NIMH Intramural Research Program ZIAMH002986-01
6 · The paper itself

Abstract

This study explores practices surrounding the operationalization of ethno-racial categories (ERCs) as confounders in biomedical research, with a focus on sickle cell disease (SCD) as a model. ERCs, often aggregate labels encompassing diverse individuals which raises questions about their relevance as confounders. Given SCD's racialization as a "Black" disease, understanding ERC utilization is crucial. This study analyzed 1,105 SCD studies published globally. Data were collected on whether ERC adjustment was employed, regional variations in ERC-adjustment rates, labels used for ERCs, rationales provided for ERC matching, and methods used for ERC determination. 28% of the studies utilized ERC adjustment, with significant regional disparities (p < 0.001). Notably, Western studies showed higher rates of ERC adjustment compared to other regions. However, crucial details such as ERC labels and methodology were frequently missing. Commonly used labels included "African" or "Black." Only 7% of studies provided explicit rationales for ERC matching, and 70% did not specify the method used for ERC determination. The findings underscore the need to adhere to guidelines on ERC operationalization in biomedicine. The lack of standardized practices raises concerns about potential biases and misinterpretations in research outcomes. Adhering to clear guidelines can mitigate the risk of perpetuating racial stereotypes and inequalities while ensuring research integrity.

Indexed as

Anemia, Sickle CellBiomedical ResearchEthnicityRacial GroupsHumansResearch DesignConfounder adjustmentEthnicityEthno-racial categoriesRaceSickle cell disease

Identifiers

PMID40055603
PMCPMC11887362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.